ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 106.8% | 97.1% | -90.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.8% | 68.3% | 49.3% | 95.5% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -150.1% | -283.8% | -462.8% | 54.5% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -157.4% | -285.6% | -425.7% | 57.7% |
| EPS Diluted | -0.52 | -0.46 | -0.35 | 0.51 |
| % Growth | -13% | -31.4% | -168.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |